510(k) Report

510(k) · Cleared

Cleared

Multiple Name

K123819510(k) TraditionalCleared Mar 5, 201383-day reviewClass I21 CFR 880.6250

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Top Calibre Sdn Bhd · LYY Latex Patient Examination Glove

Cleared on Mar 5, 2013 as substantially equivalent to K083409 (Wrp Asia Pacific Sdn. Bhd., 2009) after an 83-day review. Its family tree reaches back 2 generations to 1999.

Decided
Mar 5, 2013
Review
83 days
Class
Class I
Product code
LYY
Recalls
None
Predicates
1

Its longest line of descent runs back 2 generations to K972615 (1999). No later device cites it as a predicate yet.

  1. Root · 2 generations backK972615 Chemo Plus Powder Free Blue Latex Examination Gloves (Protein…Wembley Rubber Products (M) Sdn Bhd · 1999 · Recalled
  2. 1 generation backK083409 Powder Free Blue Latex Patient Examination Gloves, Tested for Use…Wrp Asia Pacific Sdn. Bhd. · 2009
  3. This deviceK123819 Multiple NameTop Calibre Sdn Bhd · 2013
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−2K972615Chemo Plus Powder Free Blue Latex Examination Gloves (Protein Content Labeling)Wembley Rubber Products (M) Sdn Bhd19993
−1K083409Powder Free Blue Latex Patient Examination Gloves, Tested for Use with…Wrp Asia Pacific Sdn. Bhd.2009—
0 (this device)K123819Multiple NameTop Calibre Sdn Bhd2013—
FIG. 1 — Lineage of K123819, 1999–2013Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in LYY? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new LYY device

  1. #1 K202377 Palm Care Latex Examination Powder Free Glovesscore 12.7 · 2 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K083409Powder Free Blue Latex Patient Examination Gloves, Tested for Use with Chemotherapy…
Summary page 1
…LYY, Specialty - 80 LZC, meets all of the requirements of ASTM D3578-05 (2010) Standard Specification for. Rubber Examination Glove. Predicate Device: K083409, Powder Free Blue Latex Patient Examination Glove, Tested for use with Chemotherapy Drugs with a Protein Content Label Clai…
Wrp Asia Pacific Sdn. Bhd.2009—

Also cleared against K083409: 1 other device →

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 14 years and passes through 3 companies; a new generation was cleared every 10.5 years on median.
  • 1 of the 2 ancestors has a recall of any class.
  • 1 other device also cites its predicate K083409.

How does its category compare?

All LYY devices

LYY Latex Patient Examination Glove: FDA decisions, review times, recalls and adverse event reports over 20 years. 2013, this device’s year, is highlighted.

FDA decisions per year · LYY

1in 2025

2007: 122008: 132009: 72010: 132011: 112012: 112013: 62014: 32015: 32016: 42017: 42018: 22019: 12020: 12021: 82022: 142023: 22024: 12025: 1
2007high 14 (2022) · low 1 (2019)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · LYY

150in 2022

2007: 75 days median2008: 151 days median2009: 76 days median2010: 106 days median2011: 127 days median2012: 133 days median2013: 131 days median2014: 156 days median2015: 251 days median2016: 142 days median2017: 230 days median2021: 188 days median2022: 150 days median
2007high 251 (2015) · low 75 (2007)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · LYY

1in 2020

2011: 12020: 1
2007high 1 (2011) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · LYY

1in 2025

2007: 112008: 142009: 112010: 102011: 42012: 12013: 22014: 62015: 52016: 72017: 72019: 72020: 12021: 12024: 62025: 1
2007high 14 (2008) · low 0 (2018)2025

MAUDE reports naming product code LYY, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20071275011
200813151014
2009776011
201013106010
20111112714
20121113301
2013613102
2014315606
2015325105
2016414207
2017423007
20182—00
20191—07
20201—11
2021818801
20221415000
20232—00
20241—06
20251—01
20260—0—

What is it indicated for?

A patient examination glove is a disposable device intended for medical purposes that is worn on the examiner's hand to prevent contamination between patient and examiner. This glove has been tested for use with specific chemotherapy drugs listed below. Chemotherapy Drug Permeation (Minimum Breakthrough Detection Time in Minutes) Carmustine (BCNU) (3.3 mg/ml) 15.4 Cisplatin (1.0 mg/ml) >240 Cyclophosphamide (Cytoxan) (20.0 mg/ml) >240 Cytarabine (100…

Read the full statement (136 words)

A patient examination glove is a disposable device intended for medical purposes that is worn on the examiner's hand to prevent contamination between patient and examiner.

This glove has been tested for use with specific chemotherapy drugs listed below.

Chemotherapy Drug Permeation (Minimum Breakthrough Detection Time in Minutes)

Carmustine (BCNU) (3.3 mg/ml) 15.4

Cisplatin (1.0 mg/ml) >240

Cyclophosphamide (Cytoxan) (20.0 mg/ml) >240

Cytarabine (100 mg/ml) >240

Dacarbazine (DTIC) (10.0 mg/ml) >240

Doxorubicin Hydrochloride (2.0 mg/ml) >240

Etoposide (20.0 mg/ml) >240

Fluorouracil (50.0 mg/ml) >240

Ifosfamide (50.0 mg/ml) >240

Methotrexate (25 mg/ml) >240

Mitomycin C (0.5 mg/ml) >240

Mitoxantrone (2.0 mg/ml) >240

Paclitaxel (Taxol) (6.0 mg/ml) >240

Thiotepa (10.0 mg/ml) 30.6

Vincristine Sulfate (1.0 mg/ml) >240

Please note that the following drugs - Carmustine and Thiotepa have extremely short permeation times of 15.4 and 30.6 minutes, respectively.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K123819: Multiple Name.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K123819

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026